Our scientific team has invented and developed a novel ‘proteomics’ based technology and DNA array technology that enables the rapid identification/cloning of functionally important "marker" genes that are critical to cancer cell growth and survival. The proteomics discovery technology, diagnostic marker, and ‘DNA ZYM’ therapeutic agents are covered by a patent filing that incorporates 188 claims. These claims include:
Marker proteins are generated from cDNA expression libraries developed using mRNA from specific cancer tissue sites of interest (either from normal, pre-malignant, and/or malignant foci of the same patient tissue for the comparative screening assays). The application helps to identify multiple diagnostic marker proteins whose expression is associated with a specific stage of disease. As a result, MacroArray is well positioned to develop ‘panels’ of diagnostic markers for staging cancer continue to develop new markers for other disease indications in the future. |
